| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CLINICAL SCIENCE: Clinical Nephrology |
1
*Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio;
University of Illinois, School of Medicine, Chicago, Illinois;
Division of Nephrology, University of California Davis, Sacramento, California;
University of Alabama at Birmingham, Birmingham, Alabama; ||Department of Community Health, Wright State University, Boonshoft School of Medicine, Dayton, Ohio; ¶Renal Division, Washington University School of Medicine, St. Louis, Missouri; *University of California, School of Medicine, San Francisco, California; 
National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland; 
Renal Research Institute, Beth Israel Medical Center, New York, New York; 
University of Tennessee Health Science Center, Memphis, Tennessee; ||||Vanderbilt University Medical Center, Nashville, Tennessee; ¶¶University of Texas Southwestern Medical Center, Dallas, Texas; *Baylor College of Medicine, Houston, Texas
* To whom correspondence should be addressed. E-mail: tgreene{at}bio.ri.ccf.org.
| Abstract |
|---|
In the intention-to-treat analysis of the Hemodialysis Study, all-cause mortality did not differ significantly between the high versus standard hemodialysis dose groups. The association of mortality with delivered dose within each of the two randomized treatment groups was examined, and implications for observational studies were considered. Time-dependent Cox regression was used to relate the relative risk (RR) for mortality to the running mean of the achieved equilibrated Kt/V (eKt/V) over the preceding 4 mo. eKt/V was categorized by quintiles within each dose group. Analyses were controlled for case-mix factors and baseline anthropometric volume. Within each randomized dose group, mortality was elevated markedly when achieved eKt/V was in the lowest quintile (RR, 1.93; 95% confidence interval [CI], 1.40 to 2.66; P < 0.0001 in the standard-dose group; RR, 2.04; 95% CI, 1.50 to 2.76; P < 0.0001 in the high-dose group; RR relative to the middle quintiles). The mortality rate in the lowest eKt/V quintile of the high-dose group was higher than in the full standard-dose group (RR, 1.59; 95% CI, 1.29 to 1.96; P < 0.0001). Each 0.1 eKt/V unit below the group median was associated with a 58% higher mortality in the standard-dose group (P < 0.001) and a 37% higher mortality in the high-dose group (P < 0.001). The magnitude of these dose-mortality effects was seven- to 12-fold higher than the upper limit of the 95% CI from the intention-to-treat analysis. The effects were attenuated in lagged analyses but did not disappear. When dialysis dose is targeted closely, as under the controlled conditions of the Hemodialysis Study, patients with the lowest achieved dose relative to their target dose experience markedly increased mortality, to a degree that is not compatible with a biologic effect of dose. The possibility of similar (albeit smaller) biases should be considered when analyzing observational data sets relating mortality to achieved dose of dialysis.
This article has been cited by other articles:
![]() |
J. Malyszko, J.S. Malyszko, P. Kozminski, K. Pawlak, and M. Mysliwiec Adipokines, Linking Adipocytes and Vascular Function in Hemodialyzed Patients, May Also Be Possibly Related to CD146, a Novel Adhesion Molecule Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 338 - 345. [Abstract] [PDF] |
||||
![]() |
A. X. Garg, T. Greene, and N. W. Levin A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance Nephrol. Dial. Transplant., January 1, 2008; 23(1): 52 - 55. [Full Text] [PDF] |
||||
![]() |
D. W. Coyne Epoetin Dosing and Dialysis Facility Ownership Reply JAMA, August 22, 2007; 298(8): 862 - 863. [Full Text] [PDF] |
||||
![]() |
J. Himmelfarb Chronic Kidney Disease and the Public Health: Gaps in Evidence From Interventional Trials JAMA, June 20, 2007; 297(23): 2630 - 2633. [Full Text] [PDF] |
||||
![]() |
D. Van Wyck, K.-U. Eckardt, K. Uhlig, M. Rocco, and A. Levin Appraisal of Evidence and Control of Bias in the Kidney Disease Outcomes Quality Initiative Guideline Development Process Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 8 - 10. [Full Text] [PDF] |
||||
![]() |
H. Singh, J. Reed, S. Noble, J. L. Cangiano, D. B. Van Wyck, and for the United States Iron Sucrose (Venofer) Clini Effect of Intravenous Iron Sucrose in Peritoneal Dialysis Patients Who Receive Erythropoiesis-Stimulating Agents for Anemia: A Randomized, Controlled Trial Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 475 - 482. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673